Monopar Therapeutics Inc. (MNPR)
NASDAQ: MNPR · Real-Time Price · USD
109.87
-0.95 (-0.86%)
Aug 26, 2026, 10:08 AM EDT - Market open
Monopar Therapeutics Stock Forecast
Stock Price Forecast
According to 13 analysts polled by S&P Global, Monopar Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $126.31. The average 1-year stock price forecast is 14.96% higher than the current stock price, while the lowest is $100 (-8.98%) and the highest is $145 (+31.97%).
Price Target: $126.31 (+14.96%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Monopar Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 10 | 9 | 9 | 9 | 8 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 14 | 13 | 13 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Buy Reiterates $115 → $130 | Buy | Reiterates | $115 → $130 | +18.32% | Aug 17, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $125 | Buy | Reiterates | $125 | +13.77% | Aug 13, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Hold Downgrades $109 → $119 | Hold | Downgrades | $109 → $119 | +8.31% | Aug 13, 2026 |
| Barclays | Barclays | Buy Maintains $125 → $128 | Buy | Maintains | $125 → $128 | +16.50% | Aug 13, 2026 |
| JonesTrading | JonesTrading | Buy Maintains $130 | Buy | Maintains | $130 | +18.32% | Aug 12, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
28.26M
EPS This Year
-3.01
from -1.85
EPS Next Year
-1.98
from -3.01
EPS and Forward PE are based on non-GAAP adjusted numbers.